Inclusion Criteria:

          -  Must have newly diagnosed multiple myeloma with a history of a minimum of 4 cycles of
             induction therapy, have received high-dose therapy (HDT) and autologous stem cell
             transplantation (ASCT) within 12 months of the start of induction therapy, and be
             within 6 months of ASCT on the date of randomization

          -  Must have a very good partial response (VGPR) or better response assessed per
             International Myeloma Working Group (IMWG) 2016 criteria at the time of randomization

          -  Must have archived bone marrow samples collected before induction treatment (that is,
             at diagnosis) or before transplant (for example, at the end of induction) or have
             existing results on the index multiple myeloma clone based on Adaptive
             Biotechnologies' next generation sequencing (NGS)-based minimal residual disease (MRD)
             assay. Archived bone marrow samples will be used for calibration of myeloma clonal
             cells to facilitate assessment of primary end point by NGS. If an existing result on
             index myeloma clone is available from Adaptive Biotechnologies' NGS-based MRD assay,
             as part of institutional procedures, an archived bone marrow sample is not required as
             long as Adaptive Biotechnologies is able to retrieve historical results on the index
             myeloma clone form the clinical database. Any one of the following archived samples
             are required: (a) Greater than 1 milliliter (mL) viable frozen bone marrow aspirated
             aliquot (preferred) collected in an ethylenediaminetetra-acetic acid (EDTA) tube,
             frozen, and stored at a temperature of -80 centigrade (°C), or; (b) Non-decalcified
             diagnostic bone marrow aspirate clot sections (block or slides) for MRD assessment:
             (i) A formalin fixed paraffin embedded (FFPE) block of bone marrow aspirate clot, or
             slides (preferably 5, if available), 5 micrometer each, of non-decalcified bone
             marrow, or; (ii) Slides (preferably 5, if available), bone marrow aspirate smear;
             (iii) Please note, bone marrow core sections are not acceptable samples for analysis;
             (iv) In exceptional circumstances when index myeloma clone cannot be identified from
             the archived bone marrow sample, a post-transplant sample can be used to identify
             myeloma clone with permission from the sponsor

          -  Must have residual disease as defined by detectable MRD (Adaptive Biotechnologies' NGS
             based MRD assay)

          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0,
             1, or 2

        Exclusion Criteria:

          -  A history of malignancy (other than multiple myeloma) unless all treatment of that
             malignancy was completed at least 2 years before consent and the participant has no
             evidence of disease before the of date of randomization. Exceptions are squamous and
             basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other
             non-invasive lesion that in the opinion of the investigator, with concurrence with the
             sponsor's medical monitor, is considered cured with minimal risk of recurrence within
             3 years

          -  Must not have progressed on multiple myeloma (MM) therapy at any time prior to
             screening

          -  Have had prior treatment/therapy with: (a) Daratumumab or any other anti-cluster of
             differentiation 38 (CD38) therapies, (b) Focal radiation therapy within 14 days prior
             to randomization with the exception of palliative radiotherapy for symptomatic
             management but not on measurable extramedullary plasmacytoma. Radiotherapy within 14
             days prior to randomization on measurable extramedullary plasmacytoma is not permitted
             even in the setting of palliation for symptomatic management, or (c) Plasmapheresis
             within 28 days of randomization

          -  Be exhibiting clinical signs of meningeal or central nervous system involvement due to
             multiple myeloma

          -  Have known chronic obstructive pulmonary disease (COPD) with a forced expiratory
             volume in 1 second (FEV1) less than (<) 50 percent (%) of predicted normal

          -  Have known moderate or severe persistent asthma within the past 2 years or current
             uncontrolled asthma of any classification

          -  Have any of the following: (a) Known history of seropositivity for human
             immunodeficiency virus (HIV); (b) Seropositive for hepatitis B (defined by a positive
             test for hepatitis B surface antigen [HBsAg]. Participants with resolved infection
             (that is, participants who are HBsAg negative but positive for antibodies to hepatitis
             B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs])
             must be screened using real-time polymerase chain reaction (PCR) measurement of
             hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.
             EXCEPTION: Participants with serologic findings suggestive of HBV vaccination
             (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV
             vaccination, do not need to be tested for HBV DNA by PCR; (c) Seropositive for
             hepatitis C (anti-hepatitis C virus [HCV] antibody positive or HCV-RNA quantitation
             positive), except in the setting of a sustained virologic response, defined as
             aviremia at least 12 weeks after completion of antiviral therapy)